Baseline clinical and demographic characteristics of the study cohort and of individual cytogenetic subgroups
| Baseline characteristics . | t(11;14) (n = 148 [of 277]) . | +1q (n = 58 [of 260]) . | Hyperdiploidy (n = 45 [of 232]) . | Del(13q) (n = 71 [of 245]) . | Del(17p) (n = 11 [of 244]) . | HR translocations (n = 16 [of 244]) . |
|---|---|---|---|---|---|---|
| n (%)/median (IQR) . | n (%)/median (IQR) . | n (%)/median (IQR) . | n (%)/median (IQR) . | n (%)/median (IQR) . | n (%)/median (IQR) . | |
| Median age at diagnosis (N = 278) | 66.2 (59.6-70.9) | 63.9 (57.6-72.4) | 65.8 (56.4-70.7) | 65.8 (58.5-71.4) | 66.8 (59.4-72.3) | 66.3 (62.3-71.4) |
| Sex (N = 283) | ||||||
| Male | 97 (65.5) | 30 (51.7) | 30 (66.7) | 46 (64.8) | 9 (81.8) | 9 (56.2) |
| Female | 51 (34.5) | 28 (48.3) | 15 (33.3) | 25 (35.2) | 2 (18.2) | 7 (43.8) |
| NYHA class (N = 234) | ||||||
| I | 41 (33.1) | 17 (35.4) | 10 (25.6) | 18 (32.7) | 2 (22.2) | 4 (28.6) |
| II | 50 (40.3) | 14 (29.2) | 17 (43.6) | 18 (32.7) | 5 (55.6) | 4 (28.6) |
| III | 30 (24.2) | 16 (33.3) | 12 (30.8) | 17 (30.9) | 2 (22.2) | 5 (35.7) |
| IV | 3 (2.4) | 1 (2.1) | 0 (0.0) | 2 (3.6) | 0 (0.0) | 1 (7.1) |
| Immunoglobulin | ||||||
| Involved light chain (N = 283) | ||||||
| Lambda | 118 (79.7) | 52 (89.7) | 34 (75.6) | 58 (81.7) | 9 (81.2) | 14 (87.5) |
| Median dFLC (mg/dL) (N = 282) | 19.7 (9.5-42.7) | 36.8 (10.1-98.2) | 49.7 (9.3-102.1) | 38.1 (11.5-97.8) | 15.9 (5.7-81.9) | 15.5 (4.4-63.9) |
| Chemistry | ||||||
| Median serum albumin, mg/dL (N = 273) | 3.6 (3-4.1) | 3.45 (2.9-3.9) | 3.5 (2.9-3.9) | 3.4 (2.8-3.9) | 3.8 (2.9-4.2) | 3.3 (2.95-3.9) |
| Median eGFR, mL/min per 1.73 m2 (N = 277) | 73.7 (52.3-92.9) | 66.9 (39.4-100.7) | 73.1 (49.2-97.9) | 72.2 (45.6-91.2) | 79.8 (36.1-106.3) | 74.0 (51.5-96.7) |
| eGFR <50 | 35 (24.3) | 20 (35.1) | 11 (27.5) | 19 (27.9) | 3 (27.3) | 3 (18.8) |
| Median 24-h urine protein, g (N = 249) | 2.0 (0.3-5.2) | 2.3 (0.4-5.2) | 2.3 (0.4-6.6) | 3.0 (0.4-6.8) | 1.9 (0.9-4.7) | 0.6 (0.2-3.9) |
| UP ≥2 g | 68 (51.1) | 28 (52.8) | 20 (52.6) | 34 (55.7) | 4 (44.4) | 6 (40.0) |
| UP <2 g | 65 (48.9) | 25 (47.2) | 18 (47.4) | 27 (44.3) | 5 (55.6) | 9 (60.0) |
| Cardiac biomarkers | ||||||
| Median NT-proBNP, pg/mL (N = 260) | 2199.5 (437-5128) | 2272 (864-7565) | 2564 (1075-8487.5) | 2281.5 (609.5-7696) | 1018 (543-2605) | 1 420 (453-10 314) |
| NT-proBNP >8500∗ | 23 (16.3) | 7 (12.7) | 10 (23.8) | 13 (20.0) | 0 (0) | 4 (25.0) |
| NT-proBNP ≤8500∗ | 118 (83.7) | 48 (87.3) | 32 (76.2) | 52 (80.0) | 10 (100.0) | 12 (75.0) |
| Median hs–troponin-T (N = 196), ng/L | 50 (20.3-91.9) | 50 (29.4-108) | 58 (30-116) | 60.1 (30-121) | 56 (35-78) | 43.7 (13.3-137.3) |
| ≥ 50† | 64 (48.9) | 24 (48.0) | 27 (64.3) | 35 (59.3) | 5 (62.5) | 9 (56.3) |
| < 50† | 67 (51.2) | 26 (52.0) | 15 (35.7) | 24 (40.7) | 3 (37.5) | 7 (43.8) |
| Staging | ||||||
| Mayo 2004 stage (N = 247) | ||||||
| I | 23 (17.7) | 7 (14.3) | 2 (4.9) | 6 (10.2) | 1 (12.5) | 2 (12.5) |
| II | 43 (33.1) | 18 (36.7) | 13 (31.7) | 19 (32.2) | 2 (25.0) | 5 (31.3) |
| IIIa | 43 (33.1) | 18 (36.7) | 16 (39.0) | 22 (37.3) | 5 (62.5) | 5 (31.3) |
| IIIb | 21 (16.2) | 6 (12.2) | 10 (24.4) | 12 (20.3) | 0 (0.0) | 4 (25.0) |
| Mayo 2012 stage (N= 215) | ||||||
| I | 24 (21.8) | 5 (12.2) | 5 (13.5) | 8 (14.8) | 1 (11.1) | 5 (31.3) |
| II | 20 (18.2) | 7 (17.1) | 6 (16.2) | 10 (18.5) | 5 (55.6) | 3 (18.8) |
| III | 30 (27.3) | 8 (19.5) | 8 (21.6) | 14 (25.9) | 0 (0.0) | 4 (25.0) |
| IV | 36 (32.7) | 21 (51.2) | 18 (48.6) | 22 (40.7) | 3 (33.3) | 4 (25.0) |
| Median BM plasma cells, % (N = 276) | 10 (7-20) | 19.5 (10-20.5) | 16 (10-25) | 15 (9-30) | 15 (8-25) | 11 (9-20) |
| ≥10% | 96 (65.8) | 45 (77.6) | 34 (77.3) | 47 (70.2) | 8 (72.7) | 10 (66.7) |
| Cytogenetics | ||||||
| t(11;14) | ||||||
| Yes | 148 (100) | 12 (20.7) | 14 (31.1) | 26 (37.1) | 4 (36.4) | 2 (12.5) |
| No | N/A | 46 (79.3) | 31 (68.9) | 44 (62.9) | 7 (63.6) | 14 (87.5) |
| +1q | ||||||
| Yes | 12 (8.6) | 58 (100) | 15 (36.6) | 23 (34.3) | 1 (12.5) | 5 (33.3) |
| No | 127 (91.4) | N/A | 26 (63.4) | 44 (65.7) | 7 (87.5) | 10 (66.7) |
| Hyperdiploidy | ||||||
| Yes | 14 (12.1) | 15 (31.2) | 45 (100) | 12 (18.5) | 2 (25.0) | 2 (12.5) |
| No | 102 (87.9) | 33 (68.8) | N/A | 53 (81.5) | 6 (75.0) | 14 (87.5) |
| Del(13q) | ||||||
| Yes | 26 (20.9) | 23 (45.1) | 12 (27.3) | 71 (100) | 3 (30.0) | 6 (37.5) |
| No | 98 (79.0) | 28 (54.9) | 32 (72.7) | N/A | 7 (70.0) | 10 (62.5) |
| Del(17p) | ||||||
| Yes | 4 (3.2) | 1 (1.9) | 2 (4.6) | 3 (4.4) | 11 (100.0) | 0 (0.0) |
| No | 120 (96.8) | 51 (98.1) | 42 (95.5) | 65 (95.6) | N/A | 16 (100.0) |
| HR translocations | ||||||
| Yes | 2 (1.6) | 5 (9.6) | 2 (4.6) | 6 (8.8) | 0 (0.0) | 16 (100.0) |
| No | 122 (98.4) | 47 (90.4) | 42 (95.5) | 62 (91.2) | 11 (100.0) | N/A |
| Baseline characteristics . | t(11;14) (n = 148 [of 277]) . | +1q (n = 58 [of 260]) . | Hyperdiploidy (n = 45 [of 232]) . | Del(13q) (n = 71 [of 245]) . | Del(17p) (n = 11 [of 244]) . | HR translocations (n = 16 [of 244]) . |
|---|---|---|---|---|---|---|
| n (%)/median (IQR) . | n (%)/median (IQR) . | n (%)/median (IQR) . | n (%)/median (IQR) . | n (%)/median (IQR) . | n (%)/median (IQR) . | |
| Median age at diagnosis (N = 278) | 66.2 (59.6-70.9) | 63.9 (57.6-72.4) | 65.8 (56.4-70.7) | 65.8 (58.5-71.4) | 66.8 (59.4-72.3) | 66.3 (62.3-71.4) |
| Sex (N = 283) | ||||||
| Male | 97 (65.5) | 30 (51.7) | 30 (66.7) | 46 (64.8) | 9 (81.8) | 9 (56.2) |
| Female | 51 (34.5) | 28 (48.3) | 15 (33.3) | 25 (35.2) | 2 (18.2) | 7 (43.8) |
| NYHA class (N = 234) | ||||||
| I | 41 (33.1) | 17 (35.4) | 10 (25.6) | 18 (32.7) | 2 (22.2) | 4 (28.6) |
| II | 50 (40.3) | 14 (29.2) | 17 (43.6) | 18 (32.7) | 5 (55.6) | 4 (28.6) |
| III | 30 (24.2) | 16 (33.3) | 12 (30.8) | 17 (30.9) | 2 (22.2) | 5 (35.7) |
| IV | 3 (2.4) | 1 (2.1) | 0 (0.0) | 2 (3.6) | 0 (0.0) | 1 (7.1) |
| Immunoglobulin | ||||||
| Involved light chain (N = 283) | ||||||
| Lambda | 118 (79.7) | 52 (89.7) | 34 (75.6) | 58 (81.7) | 9 (81.2) | 14 (87.5) |
| Median dFLC (mg/dL) (N = 282) | 19.7 (9.5-42.7) | 36.8 (10.1-98.2) | 49.7 (9.3-102.1) | 38.1 (11.5-97.8) | 15.9 (5.7-81.9) | 15.5 (4.4-63.9) |
| Chemistry | ||||||
| Median serum albumin, mg/dL (N = 273) | 3.6 (3-4.1) | 3.45 (2.9-3.9) | 3.5 (2.9-3.9) | 3.4 (2.8-3.9) | 3.8 (2.9-4.2) | 3.3 (2.95-3.9) |
| Median eGFR, mL/min per 1.73 m2 (N = 277) | 73.7 (52.3-92.9) | 66.9 (39.4-100.7) | 73.1 (49.2-97.9) | 72.2 (45.6-91.2) | 79.8 (36.1-106.3) | 74.0 (51.5-96.7) |
| eGFR <50 | 35 (24.3) | 20 (35.1) | 11 (27.5) | 19 (27.9) | 3 (27.3) | 3 (18.8) |
| Median 24-h urine protein, g (N = 249) | 2.0 (0.3-5.2) | 2.3 (0.4-5.2) | 2.3 (0.4-6.6) | 3.0 (0.4-6.8) | 1.9 (0.9-4.7) | 0.6 (0.2-3.9) |
| UP ≥2 g | 68 (51.1) | 28 (52.8) | 20 (52.6) | 34 (55.7) | 4 (44.4) | 6 (40.0) |
| UP <2 g | 65 (48.9) | 25 (47.2) | 18 (47.4) | 27 (44.3) | 5 (55.6) | 9 (60.0) |
| Cardiac biomarkers | ||||||
| Median NT-proBNP, pg/mL (N = 260) | 2199.5 (437-5128) | 2272 (864-7565) | 2564 (1075-8487.5) | 2281.5 (609.5-7696) | 1018 (543-2605) | 1 420 (453-10 314) |
| NT-proBNP >8500∗ | 23 (16.3) | 7 (12.7) | 10 (23.8) | 13 (20.0) | 0 (0) | 4 (25.0) |
| NT-proBNP ≤8500∗ | 118 (83.7) | 48 (87.3) | 32 (76.2) | 52 (80.0) | 10 (100.0) | 12 (75.0) |
| Median hs–troponin-T (N = 196), ng/L | 50 (20.3-91.9) | 50 (29.4-108) | 58 (30-116) | 60.1 (30-121) | 56 (35-78) | 43.7 (13.3-137.3) |
| ≥ 50† | 64 (48.9) | 24 (48.0) | 27 (64.3) | 35 (59.3) | 5 (62.5) | 9 (56.3) |
| < 50† | 67 (51.2) | 26 (52.0) | 15 (35.7) | 24 (40.7) | 3 (37.5) | 7 (43.8) |
| Staging | ||||||
| Mayo 2004 stage (N = 247) | ||||||
| I | 23 (17.7) | 7 (14.3) | 2 (4.9) | 6 (10.2) | 1 (12.5) | 2 (12.5) |
| II | 43 (33.1) | 18 (36.7) | 13 (31.7) | 19 (32.2) | 2 (25.0) | 5 (31.3) |
| IIIa | 43 (33.1) | 18 (36.7) | 16 (39.0) | 22 (37.3) | 5 (62.5) | 5 (31.3) |
| IIIb | 21 (16.2) | 6 (12.2) | 10 (24.4) | 12 (20.3) | 0 (0.0) | 4 (25.0) |
| Mayo 2012 stage (N= 215) | ||||||
| I | 24 (21.8) | 5 (12.2) | 5 (13.5) | 8 (14.8) | 1 (11.1) | 5 (31.3) |
| II | 20 (18.2) | 7 (17.1) | 6 (16.2) | 10 (18.5) | 5 (55.6) | 3 (18.8) |
| III | 30 (27.3) | 8 (19.5) | 8 (21.6) | 14 (25.9) | 0 (0.0) | 4 (25.0) |
| IV | 36 (32.7) | 21 (51.2) | 18 (48.6) | 22 (40.7) | 3 (33.3) | 4 (25.0) |
| Median BM plasma cells, % (N = 276) | 10 (7-20) | 19.5 (10-20.5) | 16 (10-25) | 15 (9-30) | 15 (8-25) | 11 (9-20) |
| ≥10% | 96 (65.8) | 45 (77.6) | 34 (77.3) | 47 (70.2) | 8 (72.7) | 10 (66.7) |
| Cytogenetics | ||||||
| t(11;14) | ||||||
| Yes | 148 (100) | 12 (20.7) | 14 (31.1) | 26 (37.1) | 4 (36.4) | 2 (12.5) |
| No | N/A | 46 (79.3) | 31 (68.9) | 44 (62.9) | 7 (63.6) | 14 (87.5) |
| +1q | ||||||
| Yes | 12 (8.6) | 58 (100) | 15 (36.6) | 23 (34.3) | 1 (12.5) | 5 (33.3) |
| No | 127 (91.4) | N/A | 26 (63.4) | 44 (65.7) | 7 (87.5) | 10 (66.7) |
| Hyperdiploidy | ||||||
| Yes | 14 (12.1) | 15 (31.2) | 45 (100) | 12 (18.5) | 2 (25.0) | 2 (12.5) |
| No | 102 (87.9) | 33 (68.8) | N/A | 53 (81.5) | 6 (75.0) | 14 (87.5) |
| Del(13q) | ||||||
| Yes | 26 (20.9) | 23 (45.1) | 12 (27.3) | 71 (100) | 3 (30.0) | 6 (37.5) |
| No | 98 (79.0) | 28 (54.9) | 32 (72.7) | N/A | 7 (70.0) | 10 (62.5) |
| Del(17p) | ||||||
| Yes | 4 (3.2) | 1 (1.9) | 2 (4.6) | 3 (4.4) | 11 (100.0) | 0 (0.0) |
| No | 120 (96.8) | 51 (98.1) | 42 (95.5) | 65 (95.6) | N/A | 16 (100.0) |
| HR translocations | ||||||
| Yes | 2 (1.6) | 5 (9.6) | 2 (4.6) | 6 (8.8) | 0 (0.0) | 16 (100.0) |
| No | 122 (98.4) | 47 (90.4) | 42 (95.5) | 62 (91.2) | 11 (100.0) | N/A |